Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
SARA suppresses myofibroblast precursor transdifferentiation in fibrogenesis in a mouse model of scleroderma
Katia Corano Scheri, Xiaoyan Liang, Vidhi Dalal, I. Caroline Le Poole, John Varga, Tomoko Hayashida
Katia Corano Scheri, Xiaoyan Liang, Vidhi Dalal, I. Caroline Le Poole, John Varga, Tomoko Hayashida
View: Text | PDF
Research Article Cell biology

SARA suppresses myofibroblast precursor transdifferentiation in fibrogenesis in a mouse model of scleroderma

  • Text
  • PDF
Abstract

We previously reported that Smad anchor for receptor activation (SARA) plays a critical role in maintaining epithelial cell phenotype. Here, we show that SARA suppressed myofibroblast precursor transdifferentiation in a mouse model of scleroderma. Mice overexpressing SARA specifically in PDGFR-β+ pericytes and pan-leukocytes (SARATg) developed significantly less skin fibrosis in response to bleomycin injection compared with wild-type littermates (SARAWT). Single-cell RNA-Seq analysis of skin PDGFR-β+ cells implicated pericyte subsets assuming myofibroblast characteristics under fibrotic stimuli, and SARA overexpression blocked the transition. In addition, a cluster that expresses molecules associated with Th2 cells and macrophage activation was enriched in SARAWT mice, but not in SARATg mice, after bleomycin treatment. Th2-specific Il-31 expression was increased in skin of the bleomycin-treated SARAWT mice and patients with scleroderma (or systemic sclerosis, SSc). Receptor-ligand analyses indicated that lymphocytes mediated pericyte transdifferentiation in SARAWT mice, while with SARA overexpression the myofibroblast activity of pericytes was suppressed. Together, these data suggest a potentially novel crosstalk between myofibroblast precursors and immune cells in the pathogenesis of SSc, in which SARA plays a critical role.

Authors

Katia Corano Scheri, Xiaoyan Liang, Vidhi Dalal, I. Caroline Le Poole, John Varga, Tomoko Hayashida

×

Figure 1

Effect of SARA overexpression in suppressing skin fibrosis in a mouse model of SSc.

Options: View larger image (or click on image) Download as PowerPoint
Effect of SARA overexpression in suppressing skin fibrosis in a mouse mo...
Representative images of hematoxylin-eosin (H&E) staining of the mouse skin from females (A) and males (B) subjected to PBS (left) or bleomycin (right) are shown. Dermal thickness is shown separately for female and male samples in the graphs (C). Each dot represents the value from a different mouse, and the average ± SEM for each condition is overlaid. mRNA expression for profibrotic gene Col1a1 and for activated myofibroblast marker Acta2 are shown (D). Masson’s trichrome staining and collagen protein deposition in skin are shown (E and F). Scale bar = 100 μm. SARAWT mice n = 14 (PBS treated n = 7 and bleomycin treated n = 7) versus SARATg mice n = 15 (PBS treated n = 7 and bleomycin treated n = 7). One-way ANOVA followed by Tukey’s multiple comparisons test: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts